The Science Journal of the American Association for Respiratory Care

2007 OPEN FORUM Abstracts

THE AEROSOL PROPERTIES OF ARFORMOTEROL TARTRATE INHALATION SOLUTION IN FIVE NEBULIZER/COMPRESSOR SYSTEMS

A. Bauer1, P. McGlynn1, L. Bovet2, P. Mims2


Background: Aerosol inhalation of bronchodilator medications is used by approximately 25% of patients with COPD. Jet nebulizers can vary significantly in drug output. The purpose of this study was to compare the aerosol properties of arformoterol inhalation solution delivered by the Pari LC Plus® nebulizer/Duraneb 3000® Portable Aerosol system with that of 4 other commonly used systems in the home care market.

Methods: The delivered dose of arformoterol was expressed as the percent of the nominal dose, 15 µg (collected in a glass Dreschel-type apparatus). The fine droplet fraction of the delivered dose was assessed by Andersen cascade impaction (ACI). Droplet size (average median diameter and average percent <5.0 µm) was assessed by laser diffraction (HELOS; Sympatec Inc.). All were determined using 15 µg/2mL arformoterol inhalation solution. Compressor flow rate measurements were taken after 1 and 6 min by placing the flow meter in line with each system.

Results: The results are presented in the table below. The Pari LC Star and Invacare systems provided higher delivered doses and fine droplet fractions compared with the Pari LC Plus system. The Salter system, on the other hand, delivered a similar dose but a smaller fine droplet fraction than the Pari LC Plus. The delivered dose and fine particle fraction for the Hudson system were comparable to the Pari LC Plus. Ranking of the nebulizer/compressor systems based on droplet size by laser diffraction (median diameter and percent <5.0 µm) was consistent with the ranking based on fine droplet fraction. Compressor flow rates varied within the range of 3.1 to 5.4 L/min.

Conclusions: The results of this study demonstrate that the choice of nebulizer/compressor system can impact some of the aerosol properties of 15µg/2mL arformoterol inhalation solution and should be taken into consideration when prescribing nebulized medications.

 Mean Delivered Dose (%) Fine Droplet* Fraction (%) Average Median Diameter (µm) Average % <5.0 µm Compressor Flow Rate at 1 (6) Min (L/min)
Nebulizer/Compressor System (n=6) (n=4) (n=6) (n=6) (n=3)
Salter®/Salter Aire Plus® 23 61 6.8 39.6 5.4 (5.4)
Updraft II Opti-Neb® Hudson Mini-Neb® 24 93 3.4 67.3 4.8 (4.8)
Pari LC Plus®Duraneb 3000® 25 89 3.4 67.0 3.2 (3.1)
Pari LC Star®/Pari Trek® 31 100 2.5 83.5 3.7 (3.7)
Sidestream®/Invacare® Envoy 35 93 2.4 88.4 4.9 (4.9)

n = number of replications
* % of mean delivered dose


You are here: RCJournal.com » Past OPEN FORUM Abstracts » 2007 Abstracts » THE AEROSOL PROPERTIES OF ARFORMOTEROL TARTRATE INHALATION SOLUTION IN FIVE NEBULIZER/COMPRESSOR SYSTEMS